Biomarker Analyses from a Placebo-Controlled Phase II Study Evaluating Erlotinib ± Onartuzumab in Advanced Non–Small Cell Lung Cancer: MET Expression Levels Are Predictive of Patient Benefit

Abstract

MET IHC remains the most robust predictor of OS and progression-free survival benefit from O+E relative to all examined exploratory markers.